{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T19:37:14Z","timestamp":1787341034149,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PE-2016-02361261"],"award-info":[{"award-number":["PE-2016-02361261"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chromosome 1q21 copy number alterations (1q21+) are among the most frequent secondary events in multiple myeloma (MM), correlating with poor prognosis and therapy resistance. However, the molecular drivers of this lesion remain poorly defined. Here, we identify PYGO2, a Wnt\/\u03b2-catenin co-activator located on 1q21, as a critical effector of MM progression. Analysis of primary CD138\n                    <jats:sup>+<\/jats:sup>\n                    plasma cells and public datasets revealed that\n                    <jats:italic>PYGO2<\/jats:italic>\n                    expression is significantly increased in 1q21+ patients and correlates with chromosome 1q copy number. High\n                    <jats:italic>PYGO2<\/jats:italic>\n                    levels were associated with adverse cytogenetics and shorter progression-free and overall survival. Functional studies showed that\n                    <jats:italic>PYGO2<\/jats:italic>\n                    knockdown (KD) in 1q21+ cell lines impaired proliferation, induced cell cycle perturbation coupled with CCND1 downregulation and reduced H3K4me3 enrichment, while increasing Carfilzomib and Bortezomib sensitivity. Conversely,\n                    <jats:italic>PYGO2<\/jats:italic>\n                    overexpression enhanced cell growth and proteasome inhibitor resistance. RNA-seq profiling of KD cells revealed coordinated suppression of canonical Wnt\/TCF target genes involved in proliferation and reshaped the replication stress and DNA damage response transcriptome, suggesting enhanced replication stress. RNA-seq profiling of KD cells also revealed suppression of oncogenic and immunomodulatory pathways, suggesting a broader role in tumor-microenvironment crosstalk. Overall, our data establish\n                    <jats:italic>PYGO2<\/jats:italic>\n                    as a previously unrecognized effector of 1q21-driven aggressiveness in MM and suggest that it represents a therapeutic vulnerability in high-risk 1q21+ MM patients.\n                  <\/jats:p>","DOI":"10.1038\/s41417-026-01060-5","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:15:45Z","timestamp":1783721745000},"page":"919-930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PYGO2 is overexpressed in multiple myeloma patients with 1q21 amplification, driving plasma cell proliferation and cell cycle progression"],"prefix":"10.1038","volume":"33","author":[{"given":"Nicolas Thomas","family":"Iannozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Storti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Vescovini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Sitzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0753-1248","authenticated-orcid":false,"given":"Andrea","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giannalisa","family":"Todaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Sammarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Toscani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Dessena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana","family":"Lungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazel","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Scita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matia","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Benedetta","family":"Dalla Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1688-7841","authenticated-orcid":false,"given":"Bruno","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza Anna Maria","family":"Lagrasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-4810","authenticated-orcid":false,"given":"Federico","family":"Quaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Donofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3457-3774","authenticated-orcid":false,"given":"Nicola","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"1060_CR1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1159\/000520312","volume":"44","author":"M Heider","year":"2021","unstructured":"Heider M, Nickel K, Hogner M, Bassermann F. Multiple myeloma: molecular pathogenesis and disease evolution. Oncol Res Treat. 2021;44:672\u201381.","journal-title":"Oncol Res Treat"},{"key":"1060_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.","journal-title":"Nat Rev Dis Primers"},{"key":"1060_CR3","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/17474086.2021.1983427","volume":"14","author":"K Bisht","year":"2021","unstructured":"Bisht K, Walker B, Kumar SK, Spicka I, Moreau P, Martin T, et al. Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. Expert Rev Hematol. 2021;14:1099\u2013114.","journal-title":"Expert Rev Hematol"},{"key":"1060_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, double-hit group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33:159\u201370.","journal-title":"Leukemia"},{"key":"1060_CR5","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","volume":"108","author":"I Hanamura","year":"2006","unstructured":"Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108:1724\u201332.","journal-title":"Blood"},{"key":"1060_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1365-2141.2006.06481.x","volume":"136","author":"KL Wu","year":"2007","unstructured":"Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, et al. Abnormalities of chromosome 1p\/q are highly associated with chromosome 13\/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol. 2007;136:615\u201323.","journal-title":"Br J Haematol"},{"key":"1060_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1200\/EDBK_200879","volume":"38","author":"A Perrot","year":"2018","unstructured":"Perrot A, Corre J, Avet-Loiseau H. Risk stratification and targets in multiple myeloma: from genomics to the bedside. Am Soc Clin Oncol Educ book. 2018;38:675\u201380.","journal-title":"Am Soc Clin Oncol Educ book"},{"key":"1060_CR8","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino M, Ruggeri M, Aquino S, Giuliani N, Arigoni M, Gentile M, et al. Impact of gain and amplification of 1q in newly diagnosed multiple myeloma patients receiving carfilzomib-based treatment in the Forte trial. Blood. 2020;136:38\u201340.","DOI":"10.1182\/blood-2020-137060"},{"key":"1060_CR9","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2010-12-328252","volume":"118","author":"JD Shaughnessy Jr","year":"2011","unstructured":"Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as a novel high-risk feature in myeloma treated with Total Therapy 3. Blood. 2011;118:3512\u201324.","journal-title":"Blood"},{"key":"1060_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0254-0","volume":"9","author":"TM Schmidt","year":"2019","unstructured":"Schmidt TM, Barwick BG, Joseph N, Heffner LT, Hofmeister CC, Bernal L, et al. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019;9:94.","journal-title":"Blood Cancer J"},{"key":"1060_CR11","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1182\/blood-2006-07-038703","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109:4995\u20135001.","journal-title":"Blood"},{"key":"1060_CR12","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3324\/haematol.2019.221176","volume":"105","author":"PJ Teoh","year":"2020","unstructured":"Teoh PJ, Chung TH, Chng PYZ, Toh SHM, Chng WJ. IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification. Haematologica. 2020;105:1391\u2013404.","journal-title":"Haematologica"},{"key":"1060_CR13","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","volume":"19","author":"S Wuilleme-Toumi","year":"2005","unstructured":"Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005;19:1248\u201352.","journal-title":"Leukemia"},{"key":"1060_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ccell.2017.05.011","volume":"32","author":"M Marchesini","year":"2017","unstructured":"Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D\u2019Anca M, et al. ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell. 2017;32:88\u2013100.e6.","journal-title":"Cancer Cell"},{"key":"1060_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1182\/blood.2024025102","volume":"146","author":"R Sklavenitis-Pistofidis","year":"2025","unstructured":"Sklavenitis-Pistofidis R, Lightbody ED, Reidy M, Tsuji J, Alberge JB, Aranha MP, et al. Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q. Blood. 2025;146:89\u2013103.","journal-title":"Blood"},{"key":"1060_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","volume":"29","author":"Y Pei","year":"2016","unstructured":"Pei Y, Liu KW, Wang J, Garancher A, Tao R, Esparza LA, et al. HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma. Cancer Cell. 2016;29:311\u201323.","journal-title":"Cancer Cell"},{"key":"1060_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-346","volume":"13","author":"Y Liu","year":"2013","unstructured":"Liu Y, Dong QZ, Wang S, Fang CQ, Miao Y, Wang L, et al. Abnormal expression of Pygopus 2 correlates with a malignant phenotype in human lung cancer. BMC Cancer. 2013;13:346.","journal-title":"BMC Cancer"},{"key":"1060_CR18","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1038\/onc.2016.10","volume":"35","author":"ZM Zhang","year":"2016","unstructured":"Zhang ZM, Wu JF, Luo QC, Liu QF, Wu QW, Ye GD, et al. Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt\/beta-catenin pathway. Oncogene. 2016;35:4787\u201397.","journal-title":"Oncogene"},{"key":"1060_CR19","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1158\/0008-5472.CAN-17-3564","volume":"78","author":"X Lu","year":"2018","unstructured":"Lu X, Pan X, Wu CJ, Zhao D, Feng S, Zang Y, et al. An in vivo screen identifies PYGO2 as a driver for metastatic prostate cancer. Cancer Res. 2018;78:3823\u201333.","journal-title":"Cancer Res"},{"key":"1060_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12079-018-0476-0","volume":"13","author":"Y Liang","year":"2019","unstructured":"Liang Y, Wang C, Chen A, Zhu L, Zhang J, Jiang P, et al. Immunohistochemistry analysis of Pygo2 expression in central nervous system tumors. J Cell Commun Signal. 2019;13:75\u201384.","journal-title":"J Cell Commun Signal"},{"key":"1060_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1083\/jcb.200810133","volume":"185","author":"B Gu","year":"2009","unstructured":"Gu B, Sun P, Yuan Y, Moraes RC, Li A, Teng A, et al. Pygo2 expands mammary progenitor cells by facilitating histone H3 K4 methylation. J Cell Biol. 2009;185:811\u201326.","journal-title":"J Cell Biol"},{"key":"1060_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0092-8674(02)00679-7","volume":"109","author":"T Kramps","year":"2002","unstructured":"Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S, et al. Wnt\/wingless signaling requires BCL9\/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell. 2002;109:47\u201360.","journal-title":"Cell"},{"key":"1060_CR23","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1128\/MCB.00465-10","volume":"30","author":"J Chen","year":"2010","unstructured":"Chen J, Luo Q, Yuan Y, Huang X, Cai W, Li C, et al. Pygo2 associates with MLL2 histone methyltransferase and GCN5 histone acetyltransferase complexes to augment Wnt target gene expression and breast cancer stem-like cell expansion. Mol Cell Biol. 2010;30:5621\u201335.","journal-title":"Mol Cell Biol"},{"key":"1060_CR24","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.humpath.2011.08.013","volume":"43","author":"J Zhang","year":"2012","unstructured":"Zhang J, Gill AJ, Issacs JD, Atmore B, Johns A, Delbridge LW, et al. The Wnt\/beta-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer. Hum Pathol. 2012;43:1044\u201350.","journal-title":"Hum Pathol"},{"key":"1060_CR25","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1002\/ar.22592","volume":"295","author":"S Zhang","year":"2012","unstructured":"Zhang S, Li Y, Wu Y, Shi K, Bing L, Hao J. Wnt\/beta-catenin signaling pathway upregulates c-Myc expression to promote cell proliferation of P19 teratocarcinoma cells. Anat Rec. 2012;295:2104\u201313.","journal-title":"Anat Rec"},{"key":"1060_CR26","first-page":"e143","volume":"1","author":"A Suzuki","year":"2015","unstructured":"Suzuki A, Scruggs A, Iwata J. The temporal specific role of WNT\/beta-catenin signaling during myogenesis. J Nat Sci. 2015;1:e143.","journal-title":"J Nat Sci"},{"key":"1060_CR27","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3324\/haematol.2023.283200","volume":"109","author":"JB Garcia","year":"2024","unstructured":"Garcia JB, Storti P, Iannozzi NT, Marchica V, Agnelli L, Toscani D, et al. Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma. Haematologica. 2024;109:627\u201331.","journal-title":"Haematologica"},{"key":"1060_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012;30:413\u201321.","journal-title":"Nat Biotechnol"},{"key":"1060_CR29","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1016\/j.csbj.2022.06.062","volume":"20","author":"G Mazzocchetti","year":"2022","unstructured":"Mazzocchetti G, Poletti A, Solli V, Borsi E, Martello M, Vigliotta I, et al. BoBafit: a copy number clustering tool designed to refit and recalibrate the baseline region of tumors\u2019 profiles. Comput Struct Biotechnol J. 2022;20:3718\u201328.","journal-title":"Comput Struct Biotechnol J"},{"key":"1060_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"1060_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45000-z","volume":"15","author":"C Terragna","year":"2024","unstructured":"Terragna C, Poletti A, Solli V, Martello M, Zamagni E, Pantani L, et al. Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in multiple myeloma patients with specific genomic, transcriptional and adverse clinical features. Nat Commun. 2024;15:1551.","journal-title":"Nat Commun"},{"key":"1060_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep22066","volume":"6","author":"C Zhou","year":"2016","unstructured":"Zhou C, Zhang Y, Dai J, Zhou M, Liu M, Wang Y, et al. Pygo2 functions as a prognostic factor for glioma due to its up-regulation of H3K4me3 and promotion of MLL1\/MLL2 complex recruitment. Sci Rep. 2016;6:22066.","journal-title":"Sci Rep"},{"key":"1060_CR33","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1060_CR34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"1060_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade4656","volume":"8","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Zhao Y, Wen J, Liu S, Huang T, Hatial I, et al. Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Sci Immunol. 2023;8:eade4656.","journal-title":"Sci Immunol"},{"key":"1060_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39439-9","volume":"14","author":"H Wang","year":"2023","unstructured":"Wang H, Bienz M, Yan XX, Xu W. Structural basis of the interaction between BCL9-Pygo and LDB-SSBP complexes in assembling the Wnt enhanceosome. Nat Commun. 2023;14:3702.","journal-title":"Nat Commun"},{"key":"1060_CR37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.molcel.2008.03.011","volume":"30","author":"M Fiedler","year":"2008","unstructured":"Fiedler M, S\u00e1nchez-Barrena MJ, Nekrasov M, Mieszczanek J, Rybin V, M\u00fcller J, et al. Decoding of methylated histone H3 tail by the Pygo-BCL9 Wnt signaling complex. Mol Cell. 2008;30:507\u201318.","journal-title":"Mol Cell"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01060-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01060-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01060-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T19:02:28Z","timestamp":1787338948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01060-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01060-5","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NG received research funding and honoraria from Pfizer, Amgen, Takeda, Sanofi, Bristol-Myers Squibb, and GSK. The authors declare no competing financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Patient samples were obtained after informed consent according to the Declaration of Helsinki. This study was approved by the Ethics Committee Area Vasta Emilia Nord of the Regional Health Service, Italy (protocol code: 112\/2018\/TESS\/AOUPR; CE: 12\/03\/2018).","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}